Metagenomi Therapeutics (MGX) EBITDA (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported EBITDA for 4 consecutive years, with -$28.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 37.1% year-over-year to -$28.8 million in Q2 2026; TTM through Jun 2026 was -$100.6 million, a 9.53% decrease from a year earlier, with the FY2025 full-year figure at -$96.0 million, down 8.0% from the prior year.
• EBITDA was -$28.8 million for Q2 2026 at Metagenomi Therapeutics, down from -$24.6 million in the prior quarter.
• Over five years, EBITDA peaked at -$16.9 million in Q2 2024 and troughed at -$29.0 million in Q1 2024.
• A 4-year average of -$22.6 million and a median of -$22.4 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 61.85% in 2024 and gained 11.62% in 2026, its largest moves.
• Over 4 years, EBITDA stood at -$20.2 million in 2023, then decreased by 2.11% to -$20.6 million in 2024, then declined by 18.15% to -$24.4 million in 2025, then decreased by 18.08% to -$28.8 million in 2026.
• The last three EBITDA figures came in at -$28.8 million (Q2 2026), -$24.6 million (Q1 2026), and -$24.4 million (Q4 2025), per Business Quant data.